UCLA engineers have developed minuscule warehouse logistics robots that could help expedite and automate medical diagnostic technologies and other applications that move and manipulate tiny drops of fluid. The study was published in Science Robotics.
Read More
Views: 0
The Democratic Republic of the Congo (DRC), Burundi, Ghana and Zambia have licensed an Ebola vaccine, just 90 days after World Health Organization (WHO) prequalification. Registration of the vaccine is expected in additional countries in the coming weeks.
The licensing of the vaccine means that the manufacturer can stockpile and widely distribute this vaccine to African countries at risk of Ebola virus disease outbreaks. Once licensed doses are available, use of the vaccine will not require clinical trial or other research protocols.
“The approval of the Ebola vaccine by these countries is another milestone in the fight against this unforgiving disease,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “Africa has rallied to cement hard-fought progress to keep its people safe from Ebola.”
WHO accelerated the licensing and roll-out of the Ebola vaccine by certifying that it met the organization’s standards for quality, safety and efficacy in its fastest vaccine prequalification process ever, announced in November 2019.
The speed with which this has been achieved has been made possible by a different approach, where national licensing procedures were done in parallel based on one single scientific review process. Usually, these process are done one by one, which can take years. The process was led by WHO with the participation of the African Vaccine Regulatory Forum (an African network of national regulatory authorities and ethics committees), the European Medicines Agency, and Merck.
“The rapid approval of the Ebola vaccine by countries in the Africa Region helps ensure this critical prevention tool will be available when and where it is needed most,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “This kind of collaboration and innovation is a model for other health priorities.”
The injectable Ebola vaccine, Ervebo, is manufactured by Merck (known as MSD outside the US and Canada). Preliminary study results have shown a 97.5% vaccine efficacy. Data also suggests that vaccinating people who are already infected reduces their chances of dying.
In response to the ongoing Ebola outbreak in the DRC, over 290 000 people have been vaccinated under compassionate use protocols. Once licensed doses are available, use of the vaccine in DRC will no longer require these protocols
Read More
https://www.who.int/news-room/detail/14-02-2020-four-countries-in-the-african-region-license-vaccine-in-milestone-for-ebola-prevention
Views: 0
Propranolol, a beta-blocker commonly prescribed to treat irregular heart rates and other conditions, has significant anti-cancer properties, say researchers in a new clinical study published in ecancermedicalscience.
The Repurposing Drugs in Oncology (ReDO) project, an international collaboration between the Anticancer Fund, Belgium, and US based GlobalCures, says that existing and widely-used non-cancer drugs may represent a relatively untapped source of novel therapies for cancer.
Historically, pharmaceutical companies devote little time to “repurposing” existing drugs. The ReDO project hopes to change that, raising awareness by publishing a series of articles in ecancer to share evidence for using these therapies in cancer medicine.
Views: 0
A new study indicates that playing video games for a limited amount of time each week may provide benefits to children, but too much can be detrimental. The findings are published in the Annals of Neurology.
There’s much debate over the potential benefits and risks of video gaming in children and teens. To provide some clarity, Jesus Pujol, MD, of the Hospital del Mar in Spain, and his colleaguesinvestigated the relationship between weekly video game use and certain cognitive abilities and conduct-related problems.
In their study of 2442 children aged 7 to 11 years, the researchers found that playing video games for one hour per week was associated with better motor skills and higher school achievement scores, but no further benefits were observed in children playing more than two hours each week.
Views: 0
cientists at Baylor College of Medicine, the National Institutes of Health and Virginia Tech Carilion Research Institute have discovered a new mechanism in the mouse brain that regulates obesity. The study, which appears in Cell Reports today, shows that this new mechanism can potentially be targeted to treat obesity.
“It’s well known that the brain is involved in the development of obesity, but how a high-fat diet changes the brain so it triggers the accumulation of body fat is still unclear,” said senior author Dr. Makoto Fukuda, assistant professor of pediatrics at Baylor and the USDA/ARS Children’s Nutrition Research Center at Baylor and Texas Children’s Hospital.
Fukuda and colleagues studied the mouse Rap1 gene, which is expressed in a variety of tissues, including the brain where it is involved in functions such as memory and learning. Little was known, however, of the role brain Rap1 plays in energy balance.
Views: 0
How the brain responds to nicotine depends on a smoker’s belief about the nicotine content in a cigarette, according to new research from the Center for BrainHealth at The University of Texas at Dallas.
The study, recently published in Frontiers in Psychiatry, found that smoking a nicotine cigarette but believing that it lacked nicotine failed to satisfy cravings related to nicotine addiction. Contrary to their expectations, researchers found that in order to satisfy nicotine cravings, smokers had to not only smoke a cigarette with nicotine but also believe that they were smoking nicotine.
“These results suggest that for drugs to have an effect on a person, he or she needs to believe that the drug is present,” said Dr. Xiaosi Gu, assistant professor in the School of Behavioral and Brain Sciences and the study’s lead author.
Views: 0
Whether you’re an avid baker, or just love a sweet treat, it’s hard to resist the appeal of chocolate. But increasing evidence shows that resistance may not be necessary. Studies demonstrate myriad benefits of chocolate, from creating a feel-good buzz to boosting cardiovascular health. Read on to learn more, then try some healthy recipes.
The Latest Research
A recent study in the journal Heart shows that habitual chocolate consumption is linked to a lower risk of cardiovascular disease and stroke. Keeping in mind that the study only demonstrated correlation (not causation), it’s nonetheless exciting to see that among participants who consumed a relatively high volume of chocolate every day, 12% developed or died of cardiovascular disease during the 12-year study. Compare that to participants who didn’t eat chocolate at all, among whom 17.4% developed or died of the disease. How much were the chocolate-eaters consuming? About 16 to 100 grams per day, or roughly one half to two typical chocolate bars.
Views: 0
Researchers at Joslin Diabetes Center have announced the results of a study that may change how nutrition therapy is delivered to overweight and obese patients with type 2 diabetes. The “Nutrition Pathway Study” compared three models of nutrition therapy and found that a highly structured nutrition plan provides the most significant impact on A1C, body weight and lipid profiles. The study results were presented at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana.
Participants in the structured nutrition therapy arm of the study reduced A1C by an average of 0.67 percent and reduced body weight by an average of 3.5 Kg over 16 weeks. According to Osama Hamdy, M.D., Ph.D., Medical Director of the Obesity Clinical Program at Joslin Diabetes Center and lead investigator on the study, these results were achieved without increasing exercise, changing medications or undertaking behavioral changes.
“This drop in A1C due to nutrition therapy alone is much better than what we have been able to achieve with many of the current medications for type 2 diabetes ,” said Dr. Hamdy. “This is very encouraging since participants in the study have lived with type 2 diabetes for more than 10 years and were not able to control their blood glucose or weight with multiple medications.”
Views: 0
Chronic pain is one of the most prevalent, disabling and expensive public health crises in the United States. It affects more than 100 million Americans, with annual costs estimated at $635 billion, says a 2014 report from the American Pain Society.
Despite the enormous societal impact of chronic pain, present treatment options are limited to nonsteroidal anti-inflammatory drugs (NSAIDS), opioids, anticonvulsants and antidepressants, which provide pain relief to only about half of patients. Furthering the problem, prescription opioid overdoses have quadrupled since 1999. There were more than 45,000 painkiller-related deaths in 2014 alone, according to the Centers for Disease Control and Prevention.
Now, researchers at Drexel University College of Medicine are aiming to identify new molecular mechanisms involved in pain. Their latest study, published this month in Epigenetics & Chromatin, shows how one protein – acting as a master controller – can regulate the expression of a large number of genes that modulate pain.
Views: 0
The combination of type 2 diabetes and coronary artery disease can be deadly.
New research from a global study led by a physician from UConn Health has found that patients with Type 2 diabetes admitted into the hospital for congestive heart failure face a one in four chance of dying over the next 18 months.
The results were presented on June 11 at the American Diabetes Association’s (ADA) annual meeting in New Orleans and published online in the ADA journal Diabetes Care. The findings paint a much grimmer picture of the outcome for diabetes patients with severe heart disease than was previously known.
Views: 0